Related Experiment Video
Updated: Jan 8, 2026
Analysis of Gene Expression Changes in the Rat Hippocampus After Deep Brain Stimulation of the Anterior Thalamic Nucleus
Published on: March 8, 2015
Effect of Valproate on Serum BDNF and MMP-9 in Pediatric Epilepsy
Anand Borisagar1, Rachna Gupta1, Manish Narang2
1Department of Pharmacology, University College of Medical Sciences (University of Delhi) & GTB Hospital, New Delhi, India.
Insights
Pediatric epilepsy patients showed lower brain-derived neurotrophic factor (BDNF) and higher matrix metalloproteinase-9 (MMP-9) levels. Valproate treatment normalized these levels, suggesting BDNF and MMP-9 as potential biomarkers for childhood epilepsy.
Area of Science:
- Neuroscience
- Biochemistry
- Pediatric Neurology
Background:
- Brain-derived neurotrophic factor (BDNF) and matrix metalloproteinase-9 (MMP-9) are implicated in epilepsy.
- Their roles in pediatric epilepsy require further elucidation.
Purpose of the Study:
- To evaluate serum BDNF and MMP-9 levels in pediatric epilepsy patients compared to controls.
- To assess the impact of valproate treatment on these biomarkers.
Main Methods:
- A cohort of 30 pediatric epilepsy patients (1-12 years) and 30 healthy controls were studied.
- Serum BDNF and MMP-9 levels were measured at baseline and after 16 weeks of valproate treatment.
Main Results:
- Epilepsy patients exhibited lower baseline BDNF and higher MMP-9 levels than controls.
- Valproate treatment significantly increased BDNF (p<0.001) and decreased MMP-9 (p<0.001) levels.
Conclusions:
- BDNF and MMP-9 are involved in the pathogenesis of pediatric epilepsy.
- Serum BDNF and MMP-9 levels show promise as potential biomarkers for pediatric epilepsy.
- Further large-scale, long-term studies are recommended.
Background And Purpose:
In recent years, brain-derived neurotrophic factor (BDNF) and matrix metalloproteinase-9 (MMP-9) have garnered interest for their involvement in epilepsy. This study evaluated the serum levels of BDNF and MMP-9 in pediatric patients with epilepsy compared to healthy controls and assessed the effect of valproate on serum BDNF and MMP-9.
Methods:
Children aged 1 year to 12 years, diagnosed with epilepsy (n=30), and age-matched healthy controls (n=30) were included. All participants were followed up for 16 weeks and assessed for changes in serum BDNF and MMP-9 levels.
Results:
Children with epilepsy had significantly lower BDNF and higher MMP-9 levels compared to healthy controls at baseline. Following 16 weeks of treatment with valproate, BDNF levels were increased significantly (p<0.001), and MMP-9 levels decreased significantly (p<0.001).
Conclusions:
The findings suggest the involvement of BDNF and MMP-9 in the pathogenesis of epilepsy. Serum BDNF and MMP-9 levels were increased and decreased, respectively, following valproate treatment in children with epilepsy. Hence, BDNF and MMP-9 could be potential biomarkers in pediatric epilepsy. Large sample sizes and long-term studies are warranted to confirm the findings.
More Related Videos
09:07Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
Published on: August 15, 2017
10:46Author Spotlight: Obtaining High-Quality CSF and Blood Samples for Epilepsy Biomarker Discovery
Published on: September 1, 2023
Related Concept Videos
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
01:14Antiepileptic Drugs: Glutamate Antagonists